Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Phase II study of clia (cladribine, idarubicin, cytarabine) plus tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia in myeloid blast Phase

View Full Paper
Ask AI
Bookmark
Share

Authors

WWWilliam G. WierdaWMWilliam D. MarreroYAYesid Alvarado

Discussion

Loading...

Member takes

Overview

Phase II trial demonstrates high response rates for cladribine and TKI in chronic myeloid leukemia patients, suggesting potential for durable remissions.

Key Points

  • High response rates observed in newly diagnosed patients with chronic myeloid leukemia and myeloid blast phase.
  • Among frontline patients, 86% achieved an overall response after one cycle of treatment with cladribine and TKI.
  • Treatment involved a combination of cladribine, idarubicin, and tyrosine kinase inhibitor over several cycles.
  • Encouraging overall survival rates were noted, highlighting the need for further investigation into this regimen.

Cite This Study

Wierda et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e10ahttps://doi.org/10.1182/blood-2025-2010
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical characteristics and prognostic factors in myeloid blast-Phase chronic myeloid leukemia2025
  2. 2Chemotherapy free ponatinib + asciminib achieves optimal disease controlpreallohsct in advanced – CML2025 · 1 citations
  3. 3The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy2025
  4. 4A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms2025
  5. 5Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission2025